Literature DB >> 24596936

Topographic assessment of retinal pigment epithelium detachment in central serous chorioretinopathy by three-dimensional optical coherence tomography single-layer retinal pigment epithelium map.

Sandeep Saxena1, Carsten H Meyer2, Shashi R Sharma3.   

Abstract

PURPOSE: This study aims to compare the topographic distribution of retinal pigment epithelium detachment (PED) in central serous chorioretinopathy (CSC) on spectral domain optical coherence tomography (SD-OCT) single-layer retinal pigment epithelium (SL-RPE) map and fluorescein angiography for the first time.
METHODS: Twenty-seven eyes of CSC with PEDs were studied retrospectively. Topographic distribution of PEDs was documented on 50° fluorescein angiography and SD-OCT SL-RPE map on macular cube 512 × 128.
RESULTS: Quantity of PEDs ranged from 1 to 5 on SD-OCT SL-RPE map macular cube 512 × 128 and corresponding macular cube area on 50° fluorescein angiography. Topographic distribution of PEDs on SL-RPE map matched with PEDs on fluorescein angiography in the corresponding macular cube area, in all the cases (interobserver correlation = 0.9).
CONCLUSION: SD-OCT SL-RPE map is a noninvasive, three-dimensional advanced tool for documentation of topographic assessment of PEDs and obviates the need of fluorescein angiography for monitoring CSC.

Entities:  

Keywords:  Central serous chorioretinopathy; Fluorescein angiography; Pigment epithelium detachment; Single-layer retinal pigment epithelium map; Spectral domain optical coherence tomography

Year:  2013        PMID: 24596936      PMCID: PMC3572240          DOI: 10.1007/s12177-013-9099-0

Source DB:  PubMed          Journal:  J Ocul Biol Dis Infor        ISSN: 1936-8437


  9 in total

1.  Evaluation of central serous chorioretinopathy with optical coherence tomography.

Authors:  T Iida; N Hagimura; T Sato; S Kishi
Journal:  Am J Ophthalmol       Date:  2000-01       Impact factor: 5.258

2.  [Improved visualization of foveal pathologies using fourier-domain optical coherence tomography].

Authors:  Masanori Hangai; Yumiko Ojima; Akiko Yoshida; Yoshiaki Yasuno; Shuichi Makita; Toyohiko Yatagai; Nagahisa Yoshimura
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2007-07

3.  Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy.

Authors:  Pawan Gupta; Vishali Gupta; M R Dogra; Ramandeep Singh; Amod Gupta
Journal:  Int Ophthalmol       Date:  2009-01-30       Impact factor: 2.031

4.  [Three-dimensional imaging in central serous chorioretinopathy].

Authors:  G Stock; C Ahlers; R Sayegh; M Ritter; S Kolar; I Golbaz; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

5.  Experience with nontreatment of central serous choroidopathy.

Authors:  M L Klein; E M Van Buskirk; E Friedman; E Gragoudas; S Chandra
Journal:  Arch Ophthalmol       Date:  1974-04

6.  Pathogenesis of disciform detachment of the neuroepithelium.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1967-03       Impact factor: 5.258

7.  Spectral domain optical coherence tomography predates fluorescein angiography in diagnosing central serous chorioretinopathy.

Authors:  Vishali Gupta; Amod Gupta; Pawan Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

8.  Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography.

Authors:  Hisataka Fujimoto; Fumi Gomi; Taku Wakabayashi; Miki Sawa; Motokazu Tsujikawa; Yasuo Tano
Journal:  Ophthalmology       Date:  2008-04-18       Impact factor: 12.079

9.  Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography.

Authors:  Yumiko Ojima; Masanori Hangai; Manabu Sasahara; Norimoto Gotoh; Ryo Inoue; Yoshiaki Yasuno; Shuichi Makita; Toyohiko Yatagai; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Ophthalmology       Date:  2007-05-15       Impact factor: 12.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.